Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302297 | 0.91 | KMT2A (0.64) | HSD17B10ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12252326 | 0.90 | RAD52 (0.56) | HTTALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL5654271 | 0.80 | KMT2A (0.56) | CYP2C9CYP2D6TSHRUSP2HTT | |
| SCHEMBL5649705 | 0.79 | MAPK14 (0.49) | CYP2C9CYP2D6TSHRUSP2HTT | |
| SCHEMBL5653663 | 0.79 | KDM4E (0.57) | CYP2C9CYP2D6TSHRHSD17B10POLB | |
| SCHEMBL5840749 | 0.78 | POLB (0.69) | CYP2C9CYP2D6TSHRHTTPOLB | |
| SCHEMBL5651622 | 0.78 | TNKS2 (0.52) | CYP2C9CYP2D6TSHRPOLBSMN1; SMN2 | |
| SCHEMBL5654035 | 0.78 | CYP2D6 (0.53) | CYP2C9CYP2D6TSHRUSP2HTT | |
| SCHEMBL5651436 | 0.78 | CYP2C9 (0.61) | CYP2C9CYP2D6TSHRUSP2HTT | |
| SCHEMBL8302243 | 0.78 | CYP2C19 (0.54) | CYP2D6TSHRHTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | CYP2C9 2582/4885CYP2D6 3044/4885TSHR 4541/4885 |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | CYP2C9 2582/4885CYP2D6 3044/4885TSHR 4541/4885 |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | CDK1, CDK8, CDK2 | CYP2C9 1753/4885CYP2D6 2202/4885TSHR 2375/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | CYP2C9 2747/4885CYP2D6 2783/4885TSHR 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.